Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks Timothy J. Craig, MD, Robyn J. Levy,

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

What drives prescription patterns in pediatric asthma management?

The natural history of soy allergy

Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients Henriette Farkas, MD, PhD, DSc, Dorottya.

Allergen immunotherapy: A practice parameter third update

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults Peter S. Creticos, MD, Jennifer Maloney,

Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents James W. Baker, MD, Avner Reshef, MD, Dumitru Moldovan,

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks Timothy J. Craig, MD, Robyn J. Levy,

Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility

David A. Khan, MD Journal of Allergy and Clinical Immunology

Is 9 more than 2 also in allergic airway inflammation?

Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial Marko Kalliomäki, MD, PhD,

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients Henriette Farkas, MD, PhD, DSc, Dorottya.

Rising prevalence of asthma is sex-specific in a US farming population

Hereditary angioedema: Safety of long-term stanozolol therapy

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Allergy testing in predicting outcome of open food challenge to peanut

Physician needs in health informatics: Just ask the docs

A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor–associated angioedema

Treatment of chronic autoimmune urticaria with omalizumab

Nonadherence to Asthma Treatment: Getting Unstuck

Peter M. Wolfgram, MD, David B. Allen, MD

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Reply Journal of Allergy and Clinical Immunology

Respiratory sensitization of a worker to the warehouse beetle Trogoderma variabile: An index case report Jonathan A. Bernstein, MD, Marjorie S. Morgan,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Cluster analysis and prediction of treatment outcomes for chronic rhinosinusitis Zachary M. Soler, MD, MSc, J. Madison Hyer, MS, Luke Rudmik, MD, MSc,

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Andy Kusuma, MD, Anurag Relan, MD, André C

Daphne Koinis-Mitchell, PhD, Timothy Craig, DO, Cynthia A

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

What is an “eosinophilic phenotype” of asthma?

Endotyping early childhood asthma by quantitative symptom assessment

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants Roland Kaufmann, MD, Regina Fölster-Holst, MD, Peter Höger, MD,

Medication use in children with asthma in Finland from 1995 to 2006

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

Mary F. Linehan, PhD, Timothy L. Frank, MD, Michelle L

Alexandra Kazaks, MA, RD, Janet Y. Uriu-Adams, PhD, Judith S

New pathways for itching in patients with atopic dermatitis?

Bruce G. Bender, PhD, Alex Pedan, PhD, Laleh T. Varasteh, RPh, MSF

Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency Marcel Levi, MD,

Reply Journal of Allergy and Clinical Immunology

Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency Richard L. Wasserman, MD, PhD,

Guus A. Westerhof, MD, Elise M. Vollema, MD, Els J

Macrolide antibiotics and asthma treatment

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

Environmental factors and eosinophilic esophagitis

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

Negative affect, medication adherence, and asthma control in children

Safety and efficacy of repeated monthly carboplatin desensitization

Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor– associated angioedema Scott A. Hubers, MD, Kevin Kohm, MS, Shouzuo Wei,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Presentation transcript:

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks Timothy J. Craig, MD, Robyn J. Levy, MD, Richard L. Wasserman, PhD, MD, Againdra K. Bewtra, MD, David Hurewitz, MD, Krystyna Obtułowicz, MD, Avner Reshef, MD, Bruce Ritchie, MD, Dumitru Moldovan, MD, Todor Shirov, MD, Vesna Grivcheva-Panovska, MD, Peter C. Kiessling, PhD, Heinz-Otto Keinecke, MS, Jonathan A. Bernstein, MD Journal of Allergy and Clinical Immunology Volume 124, Issue 4, Pages 801-808 (October 2009) DOI: 10.1016/j.jaci.2009.07.017 Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Patient disposition by treatment group. Journal of Allergy and Clinical Immunology 2009 124, 801-808DOI: (10.1016/j.jaci.2009.07.017) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Kaplan-Meier curves for time to onset of symptom relief, as determined by patient assessment (intention-to-treat population). A, Values set to 24 hours if rescue medication was given before onset of symptom relief (primary analysis). Only the curves for as long as 4 hours after treatment are shown because values did not change thereafter through 24 hours after treatment. B, Actual values recorded (ie, values not set to 24 hours if rescue medication was given before onset of symptom relief). BW, Body weight. Journal of Allergy and Clinical Immunology 2009 124, 801-808DOI: (10.1016/j.jaci.2009.07.017) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions